Loading…
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score
Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse transcription-polymerase chain reaction-based assay that estimates the risk of distant recurrence and predicts chemotherapy benefit for patients with estrogen receptor (ER)-positive...
Saved in:
| Published in: | Modern pathology 2015-07, Vol.28 (7), p.921-931 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c485t-8e07bc7f83cfa5e2cdc63d9dbebfb2c468438495908b0da7e44d19177d6bb7813 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c485t-8e07bc7f83cfa5e2cdc63d9dbebfb2c468438495908b0da7e44d19177d6bb7813 |
| container_end_page | 931 |
| container_issue | 7 |
| container_start_page | 921 |
| container_title | Modern pathology |
| container_volume | 28 |
| creator | Turner, Bradley M Skinner, Kristin A Tang, Ping Jackson, Mary C Soukiazian, Nyrie Shayne, Michelle Huston, Alissa Ling, Marilyn Hicks, David G |
| description | Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse transcription-polymerase chain reaction-based assay that estimates the risk of distant recurrence and predicts chemotherapy benefit for patients with estrogen receptor (ER)-positive breast cancers. Studies have suggested that standard histologic variables can provide similar information. Klein and Dabbs
et al
have shown that Oncotype DX recurrence scores can be estimated by incorporating standard histologic variables into equations (Magee equations). Using a simple modification of the Magee equation, we predict the Oncotype DX recurrence score in an independent set of 283 cases. The Pearson correlation coefficient (r) for the Oncotype DX and average modified Magee recurrence scores was 0.6644 (
n
=283;
P
30 (
n
=8) or an average modified Magee recurrence score |
| doi_str_mv | 10.1038/modpathol.2015.50 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1693183317</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1693183317</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-8e07bc7f83cfa5e2cdc63d9dbebfb2c468438495908b0da7e44d19177d6bb7813</originalsourceid><addsrcrecordid>eNp1kUtPwzAQhC0EgvL4AVyQJS5cUvyIE_uIeEtFXEDiFjn2pnWVxsF2Dv33pGpBCInTHvabmdUOQueUTCnh8nrlba_TwrdTRqiYCrKHJlRwkhEmxT6aEKl4xpVgR-g4xiUhNBeSHaIjJhRnqmATZN4jYN_g0co1Dix-0XMADJ-DTs53EevO4oWLybd-7gw2wSUITuPkcR_AOpNwWgB-7YxP6x7w3QcOYIYQoDOAo_EBTtFBo9sIZ7t5gt4f7t9un7LZ6-Pz7c0sM7kUKZNAytqUjeSm0QKYsabgVtka6qZmJi9kzmWuhCKyJlaXkOeWKlqWtqjrUlJ-gq62vn3wnwPEVK1cNNC2ugM_xIoWilPJOS1H9PIPuvRD6MbrNhQjuRqzRopuKRN8jAGaqg9upcO6oqTaNFD9NFBtGqgEGTUXO-ehXoH9UXy_fATYFojjqptD-BX9r-sXb7GV9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1692049438</pqid></control><display><type>article</type><title>Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score</title><source>Nature</source><creator>Turner, Bradley M ; Skinner, Kristin A ; Tang, Ping ; Jackson, Mary C ; Soukiazian, Nyrie ; Shayne, Michelle ; Huston, Alissa ; Ling, Marilyn ; Hicks, David G</creator><creatorcontrib>Turner, Bradley M ; Skinner, Kristin A ; Tang, Ping ; Jackson, Mary C ; Soukiazian, Nyrie ; Shayne, Michelle ; Huston, Alissa ; Ling, Marilyn ; Hicks, David G</creatorcontrib><description>Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse transcription-polymerase chain reaction-based assay that estimates the risk of distant recurrence and predicts chemotherapy benefit for patients with estrogen receptor (ER)-positive breast cancers. Studies have suggested that standard histologic variables can provide similar information. Klein and Dabbs
et al
have shown that Oncotype DX recurrence scores can be estimated by incorporating standard histologic variables into equations (Magee equations). Using a simple modification of the Magee equation, we predict the Oncotype DX recurrence score in an independent set of 283 cases. The Pearson correlation coefficient (r) for the Oncotype DX and average modified Magee recurrence scores was 0.6644 (
n
=283;
P
<0.0001). 100% of cases with an average modified Magee recurrence score>30 (
n
=8) or an average modified Magee recurrence score<9 (with an available Ki-67,
n
=5) would have been correctly predicted to have a high or low Oncotype DX recurrence score, respectively. 86% (38/44) of cases with an average modified Magee recurrence score≤12, and 89% (34/38) of low grade tumors (NS<6) with an ER and PR≥150, and a Ki-67<10%, would have been correctly predicted to have a low Oncotype DX recurrence score. Using an algorithmic approach to eliminate high and low risk cases, between 5% and 23% of cases would potentially not have been sent by our institution for Oncotype DX testing, creating a potential cost savings between $56,550.00 and $282,750.00. The modified Magee recurrence score along with histologic criteria may be a cost-effective alternative to the Oncotype DX in risk stratifying certain breast cancer patients. The information needed is already generated by many pathology laboratories during the initial assessment of primary breast cancer, and the equations are free.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/modpathol.2015.50</identifier><identifier>PMID: 25932962</identifier><identifier>CODEN: MODPEO</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>13/51 ; 692/53/2423 ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Female ; Gene Expression Profiling ; Humans ; Laboratory Medicine ; Medicine ; Medicine & Public Health ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - pathology ; original-article ; Pathology ; Prognosis ; Risk ; Risk Assessment</subject><ispartof>Modern pathology, 2015-07, Vol.28 (7), p.921-931</ispartof><rights>United States & Canadian Academy of Pathology 2015</rights><rights>Copyright Nature Publishing Group Jul 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-8e07bc7f83cfa5e2cdc63d9dbebfb2c468438495908b0da7e44d19177d6bb7813</citedby><cites>FETCH-LOGICAL-c485t-8e07bc7f83cfa5e2cdc63d9dbebfb2c468438495908b0da7e44d19177d6bb7813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25932962$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turner, Bradley M</creatorcontrib><creatorcontrib>Skinner, Kristin A</creatorcontrib><creatorcontrib>Tang, Ping</creatorcontrib><creatorcontrib>Jackson, Mary C</creatorcontrib><creatorcontrib>Soukiazian, Nyrie</creatorcontrib><creatorcontrib>Shayne, Michelle</creatorcontrib><creatorcontrib>Huston, Alissa</creatorcontrib><creatorcontrib>Ling, Marilyn</creatorcontrib><creatorcontrib>Hicks, David G</creatorcontrib><title>Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse transcription-polymerase chain reaction-based assay that estimates the risk of distant recurrence and predicts chemotherapy benefit for patients with estrogen receptor (ER)-positive breast cancers. Studies have suggested that standard histologic variables can provide similar information. Klein and Dabbs
et al
have shown that Oncotype DX recurrence scores can be estimated by incorporating standard histologic variables into equations (Magee equations). Using a simple modification of the Magee equation, we predict the Oncotype DX recurrence score in an independent set of 283 cases. The Pearson correlation coefficient (r) for the Oncotype DX and average modified Magee recurrence scores was 0.6644 (
n
=283;
P
<0.0001). 100% of cases with an average modified Magee recurrence score>30 (
n
=8) or an average modified Magee recurrence score<9 (with an available Ki-67,
n
=5) would have been correctly predicted to have a high or low Oncotype DX recurrence score, respectively. 86% (38/44) of cases with an average modified Magee recurrence score≤12, and 89% (34/38) of low grade tumors (NS<6) with an ER and PR≥150, and a Ki-67<10%, would have been correctly predicted to have a low Oncotype DX recurrence score. Using an algorithmic approach to eliminate high and low risk cases, between 5% and 23% of cases would potentially not have been sent by our institution for Oncotype DX testing, creating a potential cost savings between $56,550.00 and $282,750.00. The modified Magee recurrence score along with histologic criteria may be a cost-effective alternative to the Oncotype DX in risk stratifying certain breast cancer patients. The information needed is already generated by many pathology laboratories during the initial assessment of primary breast cancer, and the equations are free.</description><subject>13/51</subject><subject>692/53/2423</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Female</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Laboratory Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>original-article</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Risk</subject><subject>Risk Assessment</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kUtPwzAQhC0EgvL4AVyQJS5cUvyIE_uIeEtFXEDiFjn2pnWVxsF2Dv33pGpBCInTHvabmdUOQueUTCnh8nrlba_TwrdTRqiYCrKHJlRwkhEmxT6aEKl4xpVgR-g4xiUhNBeSHaIjJhRnqmATZN4jYN_g0co1Dix-0XMADJ-DTs53EevO4oWLybd-7gw2wSUITuPkcR_AOpNwWgB-7YxP6x7w3QcOYIYQoDOAo_EBTtFBo9sIZ7t5gt4f7t9un7LZ6-Pz7c0sM7kUKZNAytqUjeSm0QKYsabgVtka6qZmJi9kzmWuhCKyJlaXkOeWKlqWtqjrUlJ-gq62vn3wnwPEVK1cNNC2ugM_xIoWilPJOS1H9PIPuvRD6MbrNhQjuRqzRopuKRN8jAGaqg9upcO6oqTaNFD9NFBtGqgEGTUXO-ehXoH9UXy_fATYFojjqptD-BX9r-sXb7GV9Q</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Turner, Bradley M</creator><creator>Skinner, Kristin A</creator><creator>Tang, Ping</creator><creator>Jackson, Mary C</creator><creator>Soukiazian, Nyrie</creator><creator>Shayne, Michelle</creator><creator>Huston, Alissa</creator><creator>Ling, Marilyn</creator><creator>Hicks, David G</creator><general>Nature Publishing Group US</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20150701</creationdate><title>Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score</title><author>Turner, Bradley M ; Skinner, Kristin A ; Tang, Ping ; Jackson, Mary C ; Soukiazian, Nyrie ; Shayne, Michelle ; Huston, Alissa ; Ling, Marilyn ; Hicks, David G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-8e07bc7f83cfa5e2cdc63d9dbebfb2c468438495908b0da7e44d19177d6bb7813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>13/51</topic><topic>692/53/2423</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Female</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Laboratory Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>original-article</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Risk</topic><topic>Risk Assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turner, Bradley M</creatorcontrib><creatorcontrib>Skinner, Kristin A</creatorcontrib><creatorcontrib>Tang, Ping</creatorcontrib><creatorcontrib>Jackson, Mary C</creatorcontrib><creatorcontrib>Soukiazian, Nyrie</creatorcontrib><creatorcontrib>Shayne, Michelle</creatorcontrib><creatorcontrib>Huston, Alissa</creatorcontrib><creatorcontrib>Ling, Marilyn</creatorcontrib><creatorcontrib>Hicks, David G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turner, Bradley M</au><au>Skinner, Kristin A</au><au>Tang, Ping</au><au>Jackson, Mary C</au><au>Soukiazian, Nyrie</au><au>Shayne, Michelle</au><au>Huston, Alissa</au><au>Ling, Marilyn</au><au>Hicks, David G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>28</volume><issue>7</issue><spage>921</spage><epage>931</epage><pages>921-931</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><coden>MODPEO</coden><abstract>Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse transcription-polymerase chain reaction-based assay that estimates the risk of distant recurrence and predicts chemotherapy benefit for patients with estrogen receptor (ER)-positive breast cancers. Studies have suggested that standard histologic variables can provide similar information. Klein and Dabbs
et al
have shown that Oncotype DX recurrence scores can be estimated by incorporating standard histologic variables into equations (Magee equations). Using a simple modification of the Magee equation, we predict the Oncotype DX recurrence score in an independent set of 283 cases. The Pearson correlation coefficient (r) for the Oncotype DX and average modified Magee recurrence scores was 0.6644 (
n
=283;
P
<0.0001). 100% of cases with an average modified Magee recurrence score>30 (
n
=8) or an average modified Magee recurrence score<9 (with an available Ki-67,
n
=5) would have been correctly predicted to have a high or low Oncotype DX recurrence score, respectively. 86% (38/44) of cases with an average modified Magee recurrence score≤12, and 89% (34/38) of low grade tumors (NS<6) with an ER and PR≥150, and a Ki-67<10%, would have been correctly predicted to have a low Oncotype DX recurrence score. Using an algorithmic approach to eliminate high and low risk cases, between 5% and 23% of cases would potentially not have been sent by our institution for Oncotype DX testing, creating a potential cost savings between $56,550.00 and $282,750.00. The modified Magee recurrence score along with histologic criteria may be a cost-effective alternative to the Oncotype DX in risk stratifying certain breast cancer patients. The information needed is already generated by many pathology laboratories during the initial assessment of primary breast cancer, and the equations are free.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>25932962</pmid><doi>10.1038/modpathol.2015.50</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-3952 |
| ispartof | Modern pathology, 2015-07, Vol.28 (7), p.921-931 |
| issn | 0893-3952 1530-0285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1693183317 |
| source | Nature |
| subjects | 13/51 692/53/2423 Breast Neoplasms - genetics Breast Neoplasms - pathology Female Gene Expression Profiling Humans Laboratory Medicine Medicine Medicine & Public Health Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology original-article Pathology Prognosis Risk Risk Assessment |
| title | Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T17%3A37%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20modified%20Magee%20equations%20and%20histologic%20criteria%20to%20predict%20the%20Oncotype%20DX%20recurrence%20score&rft.jtitle=Modern%20pathology&rft.au=Turner,%20Bradley%20M&rft.date=2015-07-01&rft.volume=28&rft.issue=7&rft.spage=921&rft.epage=931&rft.pages=921-931&rft.issn=0893-3952&rft.eissn=1530-0285&rft.coden=MODPEO&rft_id=info:doi/10.1038/modpathol.2015.50&rft_dat=%3Cproquest_cross%3E1693183317%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-8e07bc7f83cfa5e2cdc63d9dbebfb2c468438495908b0da7e44d19177d6bb7813%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1692049438&rft_id=info:pmid/25932962&rfr_iscdi=true |